Alterations in the intestinal microbiota of patients with severe and active Graves' orbitopathy: a cross-sectional study/Experiment 1
From BugSigDB
Reviewed Marked as Reviewed by Fatima on 2021/07/16
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Graves ophthalmopathy Congestive Ophthalmopathy,Dysthyroid Ophthalmopathy,dysthyroid/thyroid-associated orbitopathy (TAO),Edematous Ophthalmopathy,Graves' ophthalmopathy,Graves' orbitopathy,Myopathic Ophthalmopathy,thyroid eye disease (TED),Thyroid-Associated Ophthalmopathies,Thyroid-Associated Ophthalmopathy,Graves ophthalmopathy,graves ophthalmopathy
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Healthy controls
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- graves orbitopathy
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- The diagnosis of GO was established according to the EUGOGO Guidelines. The active GO was defined by a clinical activity score (CAS)≥3/7, and the severe GO was defined by NOSPECS score≥IV. CT or MRI was used to exclude any orbital space-occupying disease such as tumor or extraocular myositis.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 32
- Group 1 sample size Number of subjects in the case (exposed) group
- 33
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 4 weeks
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Ion Torrent
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- Metastats
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
- Matched on Factors on which subjects have been matched on in a case-control study
- age, sex
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- decreased
- Chao1 Abundance-based estimator of species richness
- unchanged
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- decreased
- Richness Number of species
- unchanged
Signature 1
Reviewed Marked as Reviewed by Fatima on 2021/07/16
Curated date: 2021/01/10
Curator: Rimsha Azhar
Revision editor(s): WikiWorks, LGeistlinger, Fatima, Rimsha
Source: Figure 4a, 4b, 4c
Description: Comparison of the bacterial abundance at the phylum, genus and species levels in patients with graves' orbitopathy and healthy controls
Abundance in Group 1: increased abundance in graves orbitopathy
| NCBI | Quality Control | Links |
|---|---|---|
| Bacteroidota | ||
| Segatella copri | ||
| unclassified Prevotellaceae |
Revision editor(s): WikiWorks, LGeistlinger, Fatima, Rimsha
Signature 2
Reviewed Marked as Reviewed by Fatima on 2021/07/9
Source: Figure 4a, 4b, 4c
Description: Comparison of the bacterial abundance at the phylum, genus and species levels in patients with graves' orbitopathy and healthy controls
Abundance in Group 1: decreased abundance in graves orbitopathy
